Bank of New York Mellon Corp boosted its position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA – Free Report) by 32.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 58,087 shares of the company’s stock after acquiring an additional 14,352 shares during the period. Bank of New York Mellon Corp owned 0.11% of Tyra Biosciences worth $929,000 at the end of the most recent quarter.
Several other large investors have also added to or reduced their stakes in the company. RA Capital Management L.P. increased its stake in shares of Tyra Biosciences by 43.9% in the first quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock worth $170,832,000 after purchasing an additional 3,180,155 shares in the last quarter. BVF Inc. IL boosted its holdings in Tyra Biosciences by 70.1% in the 1st quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock worth $76,444,000 after buying an additional 1,921,599 shares during the period. Vanguard Group Inc. grew its position in shares of Tyra Biosciences by 18.6% during the first quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock worth $14,757,000 after purchasing an additional 140,833 shares in the last quarter. Kynam Capital Management LP grew its position in shares of Tyra Biosciences by 51.4% during the first quarter. Kynam Capital Management LP now owns 515,190 shares of the company’s stock worth $8,449,000 after purchasing an additional 175,000 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in Tyra Biosciences by 8.8% during the 4th quarter. Wellington Management Group LLP now owns 102,436 shares of the company’s stock valued at $1,419,000 after purchasing an additional 8,324 shares during the period. Hedge funds and other institutional investors own 84.14% of the company’s stock.
Insiders Place Their Bets
In other news, CEO Todd Harris sold 5,698 shares of the firm’s stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $24.31, for a total value of $138,518.38. Following the completion of the sale, the chief executive officer now directly owns 1,496,729 shares of the company’s stock, valued at approximately $36,385,481.99. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 15.40% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
View Our Latest Analysis on Tyra Biosciences
Tyra Biosciences Stock Performance
Shares of TYRA opened at $24.36 on Friday. The stock has a market capitalization of $1.28 billion, a PE ratio of -14.50 and a beta of 1.01. The company’s fifty day moving average is $21.29 and its 200 day moving average is $18.72. Tyra Biosciences, Inc. has a fifty-two week low of $10.38 and a fifty-two week high of $25.14.
Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last posted its earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. As a group, research analysts forecast that Tyra Biosciences, Inc. will post -1.53 earnings per share for the current year.
Tyra Biosciences Profile
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Read More
- Five stocks we like better than Tyra Biosciences
- 3 Best Fintech Stocks for a Portfolio Boost
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- How to Invest in Small Cap Stocks
- MarketBeat Week in Review – 9/16 – 9/20
- Stock Splits, Do They Really Impact Investors?
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.